U.S. Renewable Energy Stock News

Earlier this month, Arcutis Biotherapeutics highlighted ongoing ZORYVE momentum, upcoming regulatory and clinical milestones, and its move to a self-sustaining financial footing, while also supporting new expert guidance on genital psoriasis care published in the American Journal of Clinical Dermatology. The combination of strengthening ZORYVE fundamentals and Arcutis-backed clinical guidance in an under-recognized psoriasis subtype underscores the company’s broader ambitions in high-need...

If you are trying to work out whether Axon Enterprise at around US$447 per share is priced for perfection or still offers value, the next sections walk through what the current numbers actually say. The stock has been volatile recently, with a decline of 7% over the past week and a gain of 13.5% over the past month. It remains down 20.6% year to date and down 42.5% over the last year, while still sitting on a 126.3% gain over three years and 194.5% over five years. Recent coverage has...

Event context and recent performance SLB (SLB) has come into focus for investors after a recent move in its share price, with the stock closing at $55.51 and showing mixed short term performance alongside stronger returns over the past year. See our latest analysis for SLB. Recent trading has been slightly softer, with the 1-day share price return down 0.61% and the 7-day share price return down 2.36%. This sits within a much stronger backdrop that includes a 90-day share price return of...

Photronics recently reported second-quarter 2026 results showing broadly flat sales at US$209.94 million year-on-year but significantly higher net income of US$31.43 million, while also issuing third-quarter guidance that points to operating margin pressures and participating in the Bank of America 2026 Global Technology Conference. The earnings release has also prompted a securities-law investigation and sharp criticism from market commentators, highlighting growing scrutiny of how...

In recent days, Centene reported strong Q1 2026 results, raised its full‑year adjusted diluted EPS guidance, and cut its debt by US$1.00 billion, while also earning a place on Bank of America’s US 1 List and renewed support from other major analysts. This combination of better‑than‑planned earnings, balance sheet strengthening, and heightened institutional attention reinforces Centene’s position as a key player in government‑sponsored healthcare and managed care. Now we’ll examine how...

Encompass Health (EHC) is back on investor radars after opening Eastside Rehabilitation Hospital in Loganville, Georgia. The 40 bed facility is a joint venture with Piedmont that expands its inpatient rehabilitation footprint in the state. See our latest analysis for Encompass Health. The recent Georgia hospital opening and new facilities planned in West Virginia come as Encompass Health’s share price, at US$103.35, shows modest momentum, with a 3.04% 90 day share price return but a 12.87%...

Neurocrine Biosciences (NasdaqGS:NBIX) reported new data on INGREZZA showing strong symptom improvements in tardive dyskinesia for patients with intellectual and developmental disabilities. Additional analyses indicated meaningful benefits and remission rates in patients with hepatic impairment, a group that often faces limited dosing options. The findings highlight functional gains and rapid symptom relief in challenging real world populations beyond the broader tardive dyskinesia...

If you are wondering whether NetScout Systems stock still offers value at current levels, it helps to compare its recent performance with what the underlying business could justify. The stock last closed at US$40.30, with returns that include a decline of 4.7% over the past week, a small fall of 0.9% over the past month, and gains of 50.1% year to date and 69.6% over the last 12 months. Recent coverage has focused on NetScout Systems as investors reassess how the company fits into the...

Hims & Hers Health (NYSE:HIMS) has introduced a new monthly Weight Loss Membership that offers more flexible access to GLP-1 treatments and ongoing medical support. The company has completed its acquisition of Eucalyptus, adding operations in markets such as Germany, Australia, and Japan and expanding its telehealth reach. These moves represent a shift in how Hims & Hers approaches weight management and global online care, with potential implications for its customer base and service...

Sociedad Química y Minera de Chile S.A. recently held a board meeting where Hernán Büchi Buc was appointed Vice Chairman and reported first-quarter 2026 results showing sales of US$1,760.11 million and net income of US$364.72 million, both higher than a year earlier. The combination of stronger earnings, higher earnings per share from continuing operations, and increased lithium sales volumes has reinforced the company’s role as a key supplier in a tight lithium market. We’ll now examine how...

In recent days, Insperity reported quarterly results showing 1.7% year-on-year revenue growth that aligned with expectations but missed full-year EPS guidance, while management highlighted ongoing margin pressure. Adding intrigue, Chairman and CEO Paul J. Sarvadi made his largest-ever open-market purchase of Insperity stock, buying about US$7.93 million of shares, underscoring insider conviction amid these operational challenges. We’ll now examine how Insperity’s EPS guidance miss and...

If you are wondering whether Amprius Technologies' current share price reflects its potential or is running ahead of itself, the valuation story is where to focus next. The stock last closed at US$16.43, after falling 24.4% over the past week and 7.1% over the past month, while still sitting on a 391.9% gain over the past year and a 74.2% return over three years. Recent coverage of Amprius Technologies has centered on its role in advanced battery technology and how investor expectations are...

Fresh commentary on DENTSPLY SIRONA (XRAY) is drawing attention to weak constant currency revenue growth, falling earnings per share, and negative returns on capital. This is raising questions about how current plans are affecting long term profitability. See our latest analysis for DENTSPLY SIRONA. The recent weakness in constant currency revenue and returns on capital appears to be weighing on sentiment. The share price is down 7.97% over 30 days and the 1 year total shareholder return has...

ServiceTitan's AI Agent is reporting major real world success at Bill Joplin’s Air Conditioning and Heating. Over 90% of more than 1,300 inbound calls converted to booked jobs, with most handled without human agents. The customer reports higher revenue, lower operating costs, and less need for seasonal hiring tied directly to the AI Agent. ServiceTitan (NasdaqGS:TTAN) is putting concrete numbers behind its AI story, with a customer case study that links its AI Agent to booked jobs and...

J.Jill (JILL) opened 2027 with Q1 revenue of US$144.4 million and basic EPS of US$0.32, alongside net income of US$4.7 million, setting a measured tone for the new fiscal year. The company has seen quarterly revenue move from US$153.6 million and EPS of US$0.76 in Q1 2026 to US$144.4 million and EPS of US$0.32 in Q1 2027. Trailing twelve month EPS now stands at US$1.39 on revenue of US$587.4 million and net income of US$20.9 million, framing a period where profitability has remained positive...

Wondering if Freeport-McMoRan at around US$62.08 is still offering value, or if most of the easy gains are already on the table? This article breaks down what the current price might be implying about the stock. The stock is up 19.5% year to date and 53.1% over the past year, even though it has fallen 12.1% in the last week and is down 3.6% over the past month. Those swings can change how investors view both upside potential and risk. Recent news coverage has focused on Freeport-McMoRan's...

Motorola Solutions (MSI) has drawn fresh attention after launching SafetyCam, a wearable AI assistant for retail and frontline workers that combines video security, voice communications, a panic button and conversational AI into a single device. See our latest analysis for Motorola Solutions. Despite the SafetyCam launch and a plan to acquire counter drone specialist D Fend Solutions, Motorola Solutions’ share price has eased around 11% over the past 90 days. However, its year to date share...

Arcosa refocuses after barge sale Arcosa (ACA) has drawn fresh attention after completing the US$450 million sale of its barge business, sharpening its focus on Construction Products and Engineered Structures and updating guidance following first quarter 2026 results. See our latest analysis for Arcosa. Despite a recent pullback, including a 1-day share price return of down 3.5% and a 1-month share price return of down 5.2% to US$122.85, Arcosa’s longer track record shows stronger momentum,...

Array Digital Infrastructure (AD) has drawn fresh attention after declaring a one time special dividend of US$11.00 per Common Share and Series A Common Share, payable on June 25, 2026, to shareholders of record on June 11. See our latest analysis for Array Digital Infrastructure. Array Digital Infrastructure’s share price has moved up 3.07% over the last day and 8.99% over 90 days, while its 1 year total shareholder return of 47.72% and very large 3 year total shareholder return above 7x...

Dividend increase puts Lowe's Companies (LOW) income profile in focus Lowe's Companies (LOW) has lifted its quarterly cash dividend to $1.25 per share, a 4% rise that continues a track record of regular payouts and ongoing increases since going public. See our latest analysis for Lowe's Companies. The dividend increase comes as the share price sits at US$216.19, with the stock down 12.43% on a year to date share price basis, while the 5 year total shareholder return of 27.66% points to a more...

Recent share price moves and what they might signal USA Rare Earth (USAR) has drawn fresh attention after a sharp pullback, with the stock down about 6% today, roughly 32% over the past week, and about 22% over the past month. That volatility sits against a year to date gain of about 48% and around 63% total return over the past year. This has prompted many investors to reassess how the company’s rare earth focus and current financial profile fit into their portfolio. See our latest analysis...

In recent weeks, Biohaven announced first-in-human dosing for BHV-8100, an oral brain-penetrant PKM2 modulator, alongside early clinical data showing deep, rapid antibody reductions with its degrader candidates BHV-1300 for Graves’ disease and BHV-1400 for IgA nephropathy. These updates highlight Biohaven’s attempt to build a differentiated portfolio that links brain energy metabolism with precision immunology across neurology and autoimmune disorders. Next, we’ll examine how Biohaven’s push...

Septerna, Inc. recently announced that detailed preclinical characterization data for SEP-479, its potent and selective oral PTH1R agonist for hypoparathyroidism, has been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting, with the program currently in an ongoing Phase 1 trial. This conference spotlight offers scientific validation and industry visibility for SEP-479’s potential to functionally replace parathyroid hormone with once-daily oral therapy, a...

Casey's General Stores (CASY) is back in focus after reporting fourth quarter and full year results that topped expectations, paired with a 14% dividend increase and a larger share repurchase authorization. See our latest analysis for Casey's General Stores. The latest earnings, dividend increase and expanded buyback have coincided with a sharp reset in expectations, with a 1 day share price return of 20.29% and year to date share price return of 64.60%. Over 5 years, a total shareholder...